Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

ICAM-1-dependent homotypic aggregates regulate CD8 T cell effector function and differentiation during T cell activation.

Zumwalde NA, Domae E, Mescher MF, Shimizu Y.

J Immunol. 2013 Oct 1;191(7):3681-93. doi: 10.4049/jimmunol.1201954. Epub 2013 Aug 30.

2.

The autoimmunity-associated gene PTPN22 potentiates toll-like receptor-driven, type 1 interferon-dependent immunity.

Wang Y, Shaked I, Stanford SM, Zhou W, Curtsinger JM, Mikulski Z, Shaheen ZR, Cheng G, Sawatzke K, Campbell AM, Auger JL, Bilgic H, Shoyama FM, Schmeling DO, Balfour HH Jr, Hasegawa K, Chan AC, Corbett JA, Binstadt BA, Mescher MF, Ley K, Bottini N, Peterson EJ.

Immunity. 2013 Jul 25;39(1):111-22. doi: 10.1016/j.immuni.2013.06.013. Epub 2013 Jul 18.

3.

Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control.

Gerner MY, Heltemes-Harris LM, Fife BT, Mescher MF.

J Immunol. 2013 Aug 1;191(3):1011-5. doi: 10.4049/jimmunol.1300652. Epub 2013 Jun 26.

4.

Randomized phase II study of IL-2 with or without an allogeneic large multivalent immunogen vaccine for the treatment of stage IV melanoma.

Jha G, Miller JS, Curtsinger JM, Zhang Y, Mescher MF, Dudek AZ.

Am J Clin Oncol. 2014 Jun;37(3):261-5. doi: 10.1097/COC.0b013e318277d5c8.

5.

Autocrine IFN-γ promotes naive CD8 T cell differentiation and synergizes with IFN-α to stimulate strong function.

Curtsinger JM, Agarwal P, Lins DC, Mescher MF.

J Immunol. 2012 Jul 15;189(2):659-68. doi: 10.4049/jimmunol.1102727. Epub 2012 Jun 15.

6.

Immunotherapy with autologous tumour antigen-coated microbeads (large multivalent immunogen), IL-2 and GM-CSF in dogs with spontaneous B-cell lymphoma.

Henson MS, Curtsinger JM, Larson VS, Klausner JS, Modiano JF, Mescher MF, Miller JS.

Vet Comp Oncol. 2011 Jun;9(2):95-105. doi: 10.1111/j.1476-5829.2010.00234.x. Epub 2010 Aug 16.

PMID:
21569195
7.

Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.

Dings RP, Vang KB, Castermans K, Popescu F, Zhang Y, Oude Egbrink MG, Mescher MF, Farrar MA, Griffioen AW, Mayo KH.

Clin Cancer Res. 2011 May 15;17(10):3134-45. doi: 10.1158/1078-0432.CCR-10-2443. Epub 2011 Jan 20.

8.

Inflammatory cytokines as a third signal for T cell activation.

Curtsinger JM, Mescher MF.

Curr Opin Immunol. 2010 Jun;22(3):333-40. doi: 10.1016/j.coi.2010.02.013. Epub 2010 Apr 2. Review.

9.

Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 T cell effector function and memory.

Agarwal P, Raghavan A, Nandiwada SL, Curtsinger JM, Bohjanen PR, Mueller DL, Mescher MF.

J Immunol. 2009 Aug 1;183(3):1695-704. doi: 10.4049/jimmunol.0900592. Epub 2009 Jul 10.

10.

Programming for CD8 T cell memory development requires IL-12 or type I IFN.

Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF.

J Immunol. 2009 Mar 1;182(5):2786-94. doi: 10.4049/jimmunol.0803484.

11.

Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells.

Gerner MY, Mescher MF.

J Immunol. 2009 Mar 1;182(5):2726-37. doi: 10.4049/jimmunol.0803479.

12.
13.

Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.

Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, Miller JS.

Am J Clin Oncol. 2008 Apr;31(2):173-81. doi: 10.1097/COC.0b013e3181573e6b.

PMID:
18391603
14.
15.

Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation.

Xiao Z, Mescher MF, Jameson SC.

J Exp Med. 2007 Oct 29;204(11):2667-77. Epub 2007 Oct 22.

16.

Activation-induced non-responsiveness (anergy) limits CD8 T cell responses to tumors.

Mescher MF, Popescu FE, Gerner M, Hammerbeck CD, Curtsinger JM.

Semin Cancer Biol. 2007 Aug;17(4):299-308. Epub 2007 Jun 23. Review.

17.

IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype.

Casey KA, Mescher MF.

J Immunol. 2007 Jun 15;178(12):7640-8.

18.

The CD8 T cell response to vaccinia virus exhibits site-dependent heterogeneity of functional responses.

Xiao Z, Curtsinger JM, Prlic M, Jameson SC, Mescher MF.

Int Immunol. 2007 Jun;19(6):733-43. Epub 2007 Jun 1.

PMID:
17545279
19.

Signal 3 availability limits the CD8 T cell response to a solid tumor.

Curtsinger JM, Gerner MY, Lins DC, Mescher MF.

J Immunol. 2007 Jun 1;178(11):6752-60.

20.

Molecular basis for checkpoints in the CD8 T cell response: tolerance versus activation.

Mescher MF, Agarwal P, Casey KA, Hammerbeck CD, Xiao Z, Curtsinger JM.

Semin Immunol. 2007 Jun;19(3):153-61. Epub 2007 Mar 26. Review.

21.

Signals required for programming effector and memory development by CD8+ T cells.

Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, Popescu F, Xiao Z.

Immunol Rev. 2006 Jun;211:81-92. Review.

PMID:
16824119
22.

Signal 3 tolerant CD8 T cells degranulate in response to antigen but lack granzyme B to mediate cytolysis.

Curtsinger JM, Lins DC, Johnson CM, Mescher MF.

J Immunol. 2005 Oct 1;175(7):4392-9.

23.

CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in CD8-mediated graft rejection and avoidance of tolerance.

Filatenkov AA, Jacovetty EL, Fischer UB, Curtsinger JM, Mescher MF, Ingulli E.

J Immunol. 2005 Jun 1;174(11):6909-17.

24.

Type I IFNs provide a third signal to CD8 T cells to stimulate clonal expansion and differentiation.

Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF.

J Immunol. 2005 Apr 15;174(8):4465-9.

25.
26.

Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Oosten LE, Blokland E, van Halteren AG, Curtsinger J, Mescher MF, Falkenburg JH, Mutis T, Goulmy E.

Blood. 2004 Jul 1;104(1):224-6. Epub 2004 Mar 18.

27.

Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.

Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF.

Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):76-83.

28.
30.
31.

The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo.

Harmala LA, Ingulli EG, Curtsinger JM, Lucido MM, Schmidt CS, Weigel BJ, Blazar BR, Mescher MF, Pennell CA.

J Immunol. 2002 Nov 15;169(10):5622-9.

32.
33.
34.
35.

Activation-induced nonresponsiveness: a Th-dependent regulatory checkpoint in the CTL response.

Tham EL, Shrikant P, Mescher MF.

J Immunol. 2002 Feb 1;168(3):1190-7.

36.
37.

Signaling alterations in activation-induced nonresponsive CD8 T cells.

Tham EL, Mescher MF.

J Immunol. 2001 Aug 15;167(4):2040-8.

38.
39.

Il-12 enhances CD8 T cell homeostatic expansion.

Kieper WC, Prlic M, Schmidt CS, Mescher MF, Jameson SC.

J Immunol. 2001 May 1;166(9):5515-21.

40.
41.
43.
44.

Signaling pathways activated by leukocyte function-associated Ag-1-dependent costimulation.

Ni HT, Deeths MJ, Li W, Mueller DL, Mescher MF.

J Immunol. 1999 May 1;162(9):5183-9.

45.

Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ T cells.

Curtsinger JM, Schmidt CS, Mondino A, Lins DC, Kedl RM, Jenkins MK, Mescher MF.

J Immunol. 1999 Mar 15;162(6):3256-62.

50.

Artificial cell surface constructs for studying receptor-ligand contributions to lymphocyte activation.

Curtsinger J, Deeths MJ, Pease P, Mescher MF.

J Immunol Methods. 1997 Nov 10;209(1):47-57.

PMID:
9448033

Supplemental Content

Loading ...
Support Center